Free Trial
NASDAQ:CMND

Clearmind Medicine Q1 2025 Earnings Report

Clearmind Medicine logo
$1.03 +0.01 (+0.98%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Clearmind Medicine EPS Results

Actual EPS
-$0.24
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Clearmind Medicine Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Clearmind Medicine Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, March 12, 2025
Conference Call Time
7:00PM ET

Upcoming Earnings

Clearmind Medicine's Q2 2025 earnings is scheduled for Thursday, June 12, 2025, with a conference call scheduled on Tuesday, June 10, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Clearmind Medicine Earnings Headlines

Feds Just Admitted It—They Can Take Your Cash
Here’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousands of smart, forward-thinking individuals are making the move—out of the system and into real, untouchable assets. Because once your funds are frozen, it’s too late.
See More Clearmind Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Clearmind Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearmind Medicine and other key companies, straight to your email.

About Clearmind Medicine

Clearmind Medicine (NASDAQ:CMND), a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

View Clearmind Medicine Profile

More Earnings Resources from MarketBeat